Advisors Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.45M | Buy |
17,228
+10,280
| +148% | +$2.42M | 0.08% | 323 |
|
|
2026
Q1 | $1.39M | Buy |
6,948
+3,612
| +108% | +$715K | 0.02% | 708 |
|
|
2025
Q4 | $631K | Sell |
3,336
-67
| -2% | -$12.9K | 0.01% | 898 |
|
|
2025
Q3 | $603K | Sell |
3,403
-131
| -4% | -$19.5K | 0.01% | 932 |
|
|
2025
Q2 | $402K | Buy |
3,534
+693
| +24% | +$74.1K | 0.01% | 986 |
|
|
2025
Q1 | $299K | Buy |
2,841
+589
| +26% | +$66.6K | 0.01% | 1047 |
|
|
2024
Q4 | $241K | Buy |
+2,252
| New | +$255K | ﹤0.01% | 1092 |
|
|
2023
Q4 | – | Sell |
-6,919
| Closed | -$415K | – | 1423 |
|
|
2023
Q3 | $415K | Sell |
6,919
-132
| -2% | -$8.69K | 0.01% | 946 |
|
|
2023
Q2 | $508K | Sell |
7,051
-49
| -0.7% | -$3.68K | 0.01% | 926 |
|
|
2023
Q1 | $522K | Sell |
7,100
-114
| -2% | -$8.1K | 0.01% | 924 |
|
|
2022
Q4 | $482K | Sell |
7,214
-4,853
| -40% | -$316K | 0.01% | 937 |
|
|
2022
Q3 | $648K | Sell |
12,067
-611
| -5% | -$35.9K | 0.01% | 867 |
|
|
2022
Q2 | $706K | Sell |
12,678
-8,283
| -40% | -$470K | 0.01% | 857 |
|
|
2022
Q1 | $1.47M | Buy |
20,961
+6,478
| +45% | +$470K | 0.02% | 687 |
|
|
2021
Q4 | $1.4M | Buy |
14,483
+3,150
| +28% | +$291K | 0.02% | 734 |
|
|
2021
Q3 | $985K | Sell |
11,333
-157
| -1% | -$12.1K | 0.02% | 827 |
|
|
2021
Q2 | $940K | Sell |
11,490
-47
| -0.4% | -$3.91K | 0.01% | 858 |
|
|
2021
Q1 | $1.1M | Sell |
11,537
-232
| -2% | -$21.9K | 0.02% | 792 |
|
|
2020
Q4 | $730K | Buy |
11,769
+2,371
| +25% | +$135K | 0.01% | 865 |
|
|
2020
Q3 | $559K | Buy |
9,398
+3,167
| +51% | +$216K | 0.01% | 889 |
|
|
2020
Q2 | $435K | Buy |
6,231
+699
| +13% | +$44.3K | 0.01% | 937 |
|
|
2020
Q1 | $251K | Sell |
5,532
-3,201
| -37% | -$181K | 0.01% | 1060 |
|
|
2019
Q4 | $568K | Sell |
8,733
-1,380
| -14% | -$92.2K | 0.01% | 947 |
|
|
2019
Q3 | $628K | Sell |
10,113
-4,417
| -30% | -$277K | 0.01% | 908 |
|
|
2019
Q2 | $1.03M | Sell |
14,530
-498
| -3% | -$36.7K | 0.02% | 770 |
|
|
2019
Q1 | $1.18M | Sell |
15,028
-284
| -2% | -$21.5K | 0.02% | 725 |
|
|
2018
Q4 | $1.3M | Buy |
15,312
+1,518
| +11% | +$162K | 0.03% | 673 |
|
|
2018
Q3 | $2.36M | Buy |
13,794
+3,532
| +34% | +$532K | 0.04% | 543 |
|
|
2018
Q2 | $1.33M | Buy |
10,262
+4,365
| +74% | +$487K | 0.02% | 742 |
|
|
2018
Q1 | $559K | Buy |
5,897
+426
| +8% | +$42.1K | 0.01% | 1030 |
|
|
2017
Q4 | $467K | Buy |
5,471
+1,617
| +42% | +$140K | 0.01% | 1092 |
|
|
2017
Q3 | $327K | Buy |
+3,854
| New | +$305K | 0.01% | 1158 |
|
Other funds holding LGND
JT
CAM
Advisors Asset Management's LGND Position: Q2 2026 in Review
Advisors Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 148% in Q2 2026, buying an estimated $2.42M and bringing the position to 17,228 shares worth $5.45M. The position accounts for 0.08% of the portfolio, ranked #323.
Advisors Asset Management first reported a position in LGND in Q3 2017 and has held it in 32 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Advisors Asset Management held 17,228 shares of Ligand Pharmaceuticals worth $5.45M as of Q2 2026.
- Advisors Asset Management bought 10,280 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.42M.
- Ligand Pharmaceuticals made up 0.08% of Advisors Asset Management's portfolio in Q2 2026, its #323 holding.
- Advisors Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 32 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.